PS
PCVX icon

Principal Securities’s Vaxcyte PCVX Stock Holding History

Principal Securities’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-155
Closed -$5.58K – 2879
2025
Q3 		$5.58K Sell
155
-77
-33% -$2.55K ﹤0.01% 2923
2025
Q2 		$7.54K Buy
232
+124
+115% +$4.07K ﹤0.01% 2741
2025
Q1 		$8.84K Hold
108
– – ﹤0.01% 2575
2024
Q4 		$8.84K Buy
108
+7
+7% +$695 ﹤0.01% 2570
2024
Q3 		$11.5K Buy
101
+49
+94% +$4.42K ﹤0.01% 2372
2024
Q2 		$3.93K Hold
52
– – ﹤0.01% 2718
2024
Q1 		$3.55K Hold
52
– – ﹤0.01% 2720
2023
Q4 		$3.27K Buy
+52
New +$2.7K ﹤0.01% 2679

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Principal Securities's PCVX Position: Q4 2025 in Review

Principal Securities sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 155 shares — an estimated $5.58K sold.

Principal Securities first reported a position in PCVX in Q4 2023 and held it in 8 quarters. The position peaked at $11.5K in Q3 2024. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Principal Securities reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 155 Vaxcyte shares in Q4 2025, an estimated $5.58K.
  • Principal Securities first reported a position in Vaxcyte in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Vaxcyte position peaked at $11.5K in Q3 2024.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.